Bob Baloh, Novartis Head of Neuroscience at NIBR (via Cedars-Sinai)

No­var­tis taps Roche's neu­ro and rare dis­ease re­search lead to run neu­ro­science re­search

Even af­ter agree­ing to sell off $20 bil­lion in shares back to Roche in No­vem­ber, No­var­tis got a bit more from its crosstown ri­val —  suc­cess­ful­ly get­ting ahold of Roche’s head of re­search for neu­ro and rare dis­ease for them­selves.

NI­BR pres­i­dent Jay Brad­ner — a well-known name here at End­points — an­nounced Bob Baloh’s ap­point­ment on Twit­ter. Baloh will be run­ning NI­BR’s neu­ro­science di­vi­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.